Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-Year experience with 336 patients at a single center

Antonio Giorgio, Luciano Tarantino, Giorgio De Stefano, Carmine Coppola, Giovanna Ferraioli

Research output: Contribution to journalArticle

Abstract

OBJECTIVE. Our objective was to report the complications that occurred in a large series of patients with primary or metastatic liver tumors treated with percutaneous saline-enhanced radiofrequency ablation under sonographic guidance at a single center during 3 years of experience. SUBJECTS AND METHODS. Between September 2000 and October 2003, 336 consecutive patients (221 men and 115 women; age range, 44-78 years; mean, 67 years) with 407 malignant liver tumors were treated at our institution using radiofrequency ablation. Of these patients, 287 had hepatocellular carcinoma from cirrhosis, 47 had liver metastases (38 from colon, six from breast, two from lung, and one from cutaneous melanoma), and two had primary cholangiocarcinoma. Adverse events related to radiofrequency ablation were prospectively recorded. RESULTS. The number of sessions performed was 375 (39 patients had two sessions). The number of patients with major complications, including death, was three (0.9%). The overall mortality rate was 0.3% (1/336). One patient died because of worsening liver decompensation. Two other major complications occurred. In one patient (0.3%), liver abscess and sepsis developed and were successfully treated with percutaneous sonography-guided needle (18-gauge) aspiration and IV antibiotics. Mild posttreatment ascites occurred in one patient (0.3%). One patient showed self-limiting subcutaneous cellulitis along the electrode-needle path that healed in 2 weeks. Fever lasting 1-3 days and pain lasting 12-24 hr were observed in 141 patients (42%) and 211 patients (63%), respectively. So far, no cutaneous or abdominal wall seeding has been observed clinically or sonographically. CONCLUSION. Radiofrequency ablation of liver tumors can be considered safe. Life-threatening acute liver failure can be considered a rare possible complication.

Original languageEnglish
Pages (from-to)207-211
Number of pages5
JournalAmerican Journal of Roentgenology
Volume184
Issue number1
Publication statusPublished - Jan 2005

Fingerprint

Liver
Neoplasms
Needles
Liver Abscess
Skin
Cellulitis
Cholangiocarcinoma
Acute Liver Failure
Abdominal Wall
Ascites
Hepatocellular Carcinoma
Melanoma
Ultrasonography
Sepsis
Electrodes
Colon
Breast
Fibrosis
Fever
Neoplasm Metastasis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors : 3-Year experience with 336 patients at a single center. / Giorgio, Antonio; Tarantino, Luciano; De Stefano, Giorgio; Coppola, Carmine; Ferraioli, Giovanna.

In: American Journal of Roentgenology, Vol. 184, No. 1, 01.2005, p. 207-211.

Research output: Contribution to journalArticle

@article{9c32c1c18d22410798992db37c2516b2,
title = "Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-Year experience with 336 patients at a single center",
abstract = "OBJECTIVE. Our objective was to report the complications that occurred in a large series of patients with primary or metastatic liver tumors treated with percutaneous saline-enhanced radiofrequency ablation under sonographic guidance at a single center during 3 years of experience. SUBJECTS AND METHODS. Between September 2000 and October 2003, 336 consecutive patients (221 men and 115 women; age range, 44-78 years; mean, 67 years) with 407 malignant liver tumors were treated at our institution using radiofrequency ablation. Of these patients, 287 had hepatocellular carcinoma from cirrhosis, 47 had liver metastases (38 from colon, six from breast, two from lung, and one from cutaneous melanoma), and two had primary cholangiocarcinoma. Adverse events related to radiofrequency ablation were prospectively recorded. RESULTS. The number of sessions performed was 375 (39 patients had two sessions). The number of patients with major complications, including death, was three (0.9{\%}). The overall mortality rate was 0.3{\%} (1/336). One patient died because of worsening liver decompensation. Two other major complications occurred. In one patient (0.3{\%}), liver abscess and sepsis developed and were successfully treated with percutaneous sonography-guided needle (18-gauge) aspiration and IV antibiotics. Mild posttreatment ascites occurred in one patient (0.3{\%}). One patient showed self-limiting subcutaneous cellulitis along the electrode-needle path that healed in 2 weeks. Fever lasting 1-3 days and pain lasting 12-24 hr were observed in 141 patients (42{\%}) and 211 patients (63{\%}), respectively. So far, no cutaneous or abdominal wall seeding has been observed clinically or sonographically. CONCLUSION. Radiofrequency ablation of liver tumors can be considered safe. Life-threatening acute liver failure can be considered a rare possible complication.",
author = "Antonio Giorgio and Luciano Tarantino and {De Stefano}, Giorgio and Carmine Coppola and Giovanna Ferraioli",
year = "2005",
month = "1",
language = "English",
volume = "184",
pages = "207--211",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "1",

}

TY - JOUR

T1 - Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors

T2 - 3-Year experience with 336 patients at a single center

AU - Giorgio, Antonio

AU - Tarantino, Luciano

AU - De Stefano, Giorgio

AU - Coppola, Carmine

AU - Ferraioli, Giovanna

PY - 2005/1

Y1 - 2005/1

N2 - OBJECTIVE. Our objective was to report the complications that occurred in a large series of patients with primary or metastatic liver tumors treated with percutaneous saline-enhanced radiofrequency ablation under sonographic guidance at a single center during 3 years of experience. SUBJECTS AND METHODS. Between September 2000 and October 2003, 336 consecutive patients (221 men and 115 women; age range, 44-78 years; mean, 67 years) with 407 malignant liver tumors were treated at our institution using radiofrequency ablation. Of these patients, 287 had hepatocellular carcinoma from cirrhosis, 47 had liver metastases (38 from colon, six from breast, two from lung, and one from cutaneous melanoma), and two had primary cholangiocarcinoma. Adverse events related to radiofrequency ablation were prospectively recorded. RESULTS. The number of sessions performed was 375 (39 patients had two sessions). The number of patients with major complications, including death, was three (0.9%). The overall mortality rate was 0.3% (1/336). One patient died because of worsening liver decompensation. Two other major complications occurred. In one patient (0.3%), liver abscess and sepsis developed and were successfully treated with percutaneous sonography-guided needle (18-gauge) aspiration and IV antibiotics. Mild posttreatment ascites occurred in one patient (0.3%). One patient showed self-limiting subcutaneous cellulitis along the electrode-needle path that healed in 2 weeks. Fever lasting 1-3 days and pain lasting 12-24 hr were observed in 141 patients (42%) and 211 patients (63%), respectively. So far, no cutaneous or abdominal wall seeding has been observed clinically or sonographically. CONCLUSION. Radiofrequency ablation of liver tumors can be considered safe. Life-threatening acute liver failure can be considered a rare possible complication.

AB - OBJECTIVE. Our objective was to report the complications that occurred in a large series of patients with primary or metastatic liver tumors treated with percutaneous saline-enhanced radiofrequency ablation under sonographic guidance at a single center during 3 years of experience. SUBJECTS AND METHODS. Between September 2000 and October 2003, 336 consecutive patients (221 men and 115 women; age range, 44-78 years; mean, 67 years) with 407 malignant liver tumors were treated at our institution using radiofrequency ablation. Of these patients, 287 had hepatocellular carcinoma from cirrhosis, 47 had liver metastases (38 from colon, six from breast, two from lung, and one from cutaneous melanoma), and two had primary cholangiocarcinoma. Adverse events related to radiofrequency ablation were prospectively recorded. RESULTS. The number of sessions performed was 375 (39 patients had two sessions). The number of patients with major complications, including death, was three (0.9%). The overall mortality rate was 0.3% (1/336). One patient died because of worsening liver decompensation. Two other major complications occurred. In one patient (0.3%), liver abscess and sepsis developed and were successfully treated with percutaneous sonography-guided needle (18-gauge) aspiration and IV antibiotics. Mild posttreatment ascites occurred in one patient (0.3%). One patient showed self-limiting subcutaneous cellulitis along the electrode-needle path that healed in 2 weeks. Fever lasting 1-3 days and pain lasting 12-24 hr were observed in 141 patients (42%) and 211 patients (63%), respectively. So far, no cutaneous or abdominal wall seeding has been observed clinically or sonographically. CONCLUSION. Radiofrequency ablation of liver tumors can be considered safe. Life-threatening acute liver failure can be considered a rare possible complication.

UR - http://www.scopus.com/inward/record.url?scp=11144264686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144264686&partnerID=8YFLogxK

M3 - Article

C2 - 15615976

AN - SCOPUS:11144264686

VL - 184

SP - 207

EP - 211

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 1

ER -